Aegis restated their buy rating on shares of CytRx (NASDAQ:CYTR) in a report issued on Monday, Analyst Ratings News reports.
Shares of CytRx (NASDAQ:CYTR) traded down 1.25% on Monday, hitting $2.37. The stock had a trading volume of 211,263 shares. CytRx has a 1-year low of $1.79 and a 1-year high of $3.65. The stock has a 50-day moving average of $2.35 and a 200-day moving average of $2.40. The company’s market cap is $99.5 million.
CytRx (NASDAQ:CYTR) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.33) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.22) by $0.11. During the same quarter in the prior year, the company posted $0.07 earnings per share. Analysts expect that CytRx will post $-0.69 EPS for the current fiscal year.
A number of other firms have also recently commented on CYTR. Analysts at Thomson Reuters/Verus downgraded shares of CytRx from a buy rating to a hold rating in a research note to investors on Monday, October 28th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. CytRx has a consensus rating of Buy and an average price target of $5.27.
CytRx Corporation as (NASDAQ:CYTR) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.